Wohua Pharmaceutical: Announcement on the inclusion of related products of the company and its subsidiaries in the "National Essential Drugs List"
Securities code: 002107 Securities abbreviation: Wohua Pharmaceutical Announcement number: 2026-023
Shandong Wohua Pharmaceutical Technology Co., Ltd.
Announcement on the inclusion of relevant products of the company and its subsidiaries into the "National Essential Drugs List"
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Recently, the National Health Commission officially released the "National Essential Medicines List (2026 Edition)" (hereinafter referred to as the "National Essential Medicines List"), which will come into effect on September 1, 2026. According to statistics, Xinskeshu Tablets, the core product of Shandong Wohua Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the company), continues to be included in the new version of the National Essential Drugs List, and the core products of Hedan Capsules and Hedan Tablets of its subsidiary Jiangxi Wohua Jishun Pharmaceutical Co., Ltd. (hereinafter referred to as Jiangxi Wohua Jishun) are included in the National Essential Drugs List for the first time.
The specific details of the new varieties added to the national essential medicine list are as follows:
1. Information on the newly added varieties included in the "National Essential Drugs Catalog"
Index "National Basics"
Serial number Number Variety name Specification Manufacturer Remarks Drug Catalog》
Each piece weighs 0.73g (similar to
Equivalent to decoction pieces 1. Internal medicine-Jiangxi Wohua Jishun Medical
1 196 Hedan tablets (Added 14.125g) (15) Lipid-lowering agent Pharmaceutical Co., Ltd.
Each capsule contains 0.33g (phase 1. Internal medicine-Jiangxi Wohua Jishun Medical
2 196 Hedan capsules newly added
Equivalent to 7.06g of decoction pieces) (15) Lipid regulating agent Pharmaceutical Co., Ltd.
Note: Hedan tablets/capsules are exclusive varieties of Jiangxi Wohua Jishun.
2. Impact on the company
This time, multiple products of the company and its subsidiaries have been included in the essential medicine catalog, which will play an important role in expanding the market coverage and increasing the sales scale of the company's above-mentioned products in the future.
Xinskeshu Tablets will continue to be included in the National Essential Drugs List this time and is the company's core product in the field of treatment of chronic diseases such as cardiovascular diseases. This time, Hedan Tablets/Capsules are newly included in the National Essential Drug List and will become the company's second blockbuster essential drug product in the above-mentioned fields. Together with Xinskeshu Tablets, they will form a "cardiovascular + lipid-lowering" dual-base drug combination. The two synergize and can provide medical institutions with a one-stop solution from cardiovascular treatment to blood lipid regulation.
At the same time, as a pure plant lipid-lowering drug that can effectively reduce patient weight while regulating blood lipids, Hedan tablets/capsules are positioned in a product that is highly consistent with the country’s emphasis on the issue of overweight nationals in recent years, which has elevated obesity prevention and treatment to a new level of national public health action. Health administrative departments at all levels have successively launched relevant activities for the “Weight Management Year” (three years from June 2024) and other policy trends. The clinical characteristics of “lipid regulation and weight loss” are also highly compatible with the core requirements of the “Weight Management Year”. Hedan Tablets/Capsules have been newly included in the National Essential Medicines List, becoming one of the two Chinese patent medicine products currently included in the National Essential Drugs List in the field of lipid-lowering medicine. This will further help prove its academic and clinical value and provide a major historical opportunity for the company to actively explore and promote Hedan Tablets/Capsules to develop a new track for "weight loss". After entering the essential medicine catalog, Hedan tablets/capsules will receive multiple policy blessings such as priority deployment by medical institutions, unified procurement by medical consortiums, and preferential medical insurance reimbursement, which will help promote its market coverage.
After the above-mentioned products of the company and its subsidiaries enter the national essential medicine list, they will not only usher in development opportunities, but may also face fierce market competition. There is certain uncertainty whether sales and income can meet expectations. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Shandong Wohua Pharmaceutical Technology Co., Ltd.
July 9, 2026